In this video which will be on Investor’s hub later tonight, early tomorrow, I give a detailed explanation on why we believe $PGNX will be headed higher from its current level, possibly breaking over $4.61. As always, Premium subscribers get…
Month: May 2014
Progenics Pharma Poised For A Potential Price Increase Ahead Of June 11th Adcom
Summary Progenics is expecting a Food and Drug Administration (FDA) Advisory Committee meeting on June 11 – 12 to decide whether or not to recommend a Supplemental New Drug Application (sNDA). The Relistor sNDA is for a subcutaneous injection for…
Market Commentary For Wed May 28 -OREX Goes Well + Reason For Small Cap Sell Off
Market Commentary For Wed May 28 -OREX Goes Well + Reason For Small Cap Sell Off $OREX hit $6.50 today, so I’m happy about it hitting where I said it had a chance to today. The markets sold off (profit…
Updated With New Chart: Catalyst Trade Alert: We Bought $PGNX Target opinion = $4.50
Catalyst: Advisory Committee Reschedule Update Progenics shares have not been high on investors’ radars in recent months because the FDA had rescheduled the set Advisory Committee (Adcom) meeting, which was due earlier this year. The FDA gave no guidance on…
Market Wrap With Chart and Macro Review May 27 2014 – $IBB And $QQQ Break Upwards
Market Wrap With Chart and Macro Review May 27 2014 – $IBB And $QQQ Break Upwards. $OREX, $SPY, $IBB, $QQQ charts covered and explained in this video. Additionally, I offer some macro commentary on the markets, enjoy! Scott NOTE: I…
Updated: Orexigen’s Weight Loss Drug Will Be Approved Soon And Will Lead Market – Here Is Why
Coming up on June 10th, 2014, Orexigen Therapeutics expects a Food and Drug Administration (FDA) for it’s weight loss drug NB32 (Contrave). Contrave was initially rejected by the FDA due to a single issue cardiovascular safety concern and requested the…
Catalyst Trade Pick – We Bought $OREX. Target – $7 +
Scott, Mike, Kyle bought $OREX, we see around $7 as run-up potential. Key point are: Coming up on June 10th, 2014, Orexigen Therapeutics expects a Food and Drug Administration (FDA) for it’s weight loss drug NB32 (Contrave). Contrave was initially…
Commentary For Monday May 26 – Ukraine Goes Smooth ECB Next
Commentary For Monday May 26 – Ukraine Goes Smooth ECB Next. Ukrainian Elections went smoothly as billionaire Petro Poroshenko won with 54% of the vote, which avoids a run-off which could have brought more uncertainty to the situation. ECB’s Dragi…
Market Wrap Up – Liquidity Love
Market Wrap Up – Liquidity Love. Not much to add in the text here, except my view this week was way off as I miscalculated the market’s love for liquidity over every factor, including the one I totally botched –…
Market Commentary For Thursday May 22 – Pivotal Point
Market Commentary For Thursday May 22 – Pivotal Point. Tomorrow’s market action should be very interesting as I’m looking for a couple of things; 1. $IBB closing over $235 = getting close to confirmation of a resumption of the up…